Status:
COMPLETED
Alternate-Day Buprenorphine Administration. Phase I - 3
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
University of Vermont
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
28-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.
Eligibility Criteria
Please contact site for information.
Key Trial Info
Start Date :
April 1 1992
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000221
Start Date
April 1 1992
Last Update
June 24 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Treatment Research Center
Burlington, Vermont, United States, 05401